New drug combo aims to shrink High-Risk prostate tumors before surgery
NCT ID NCT05726292
First seen Apr 06, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study tests whether adding the drug relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 men with advanced, localized prostate cancer that hasn't spread will take the drug combination or a placebo for 24 weeks, then have their prostate removed. The goal is to see if the new combo leads to fewer cancer cells remaining after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60453, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.